8-K: Vaxart Q2 2025: Norovirus Progress, COVID-19 Trial Halted

Vaxart announced its second quarter 2025 financial results, highlighted by positive norovirus vaccine data and a stop work order for its COVID-19 Phase 2b trial.

Summary

• Revenue for the second quarter of 2025 was $39.7 million, a significant increase from $6.4 million in the second quarter of 2024, primarily driven by government contracts.
• The company reported a net loss of $15.0 million for Q2 2025, an improvement from a net loss of $16.5 million in Q2 2024.
• Cash, cash equivalents, and investments totaled $26.3 million as of June 30, 2025, with an anticipated cash runway into the first quarter of 2026.
• Positive topline data from the Phase 1 clinical trial for its second-generation oral norovirus vaccine constructs showed statistically significant increases in GI.1 (141%) and GII.4 (94%) norovirus blocking antibodies.
• Vaxart received a stop work order on August 5, 2025, halting screening and enrollment for its COVID-19 Phase 2b trial, which had enrolled approximately 5,000 participants.
• The avian influenza vaccine demonstrated 100% protection against death in a robust ferret clade 2.3.4.4b challenge model.
• A Special Meeting of Stockholders is scheduled for September 5, 2025, to vote on a reverse stock split at a ratio of 1-for-5 to 1-for-20 to regain Nasdaq compliance.

Sentiment

Score: 4

Explanation: While Vaxart reported strong revenue growth and positive early-stage clinical data for its norovirus and influenza programs, the unexpected stop work order for its large COVID-19 Phase 2b trial and the short cash runway, coupled with the need for a reverse stock split to maintain listing, present significant operational and financial challenges.

Positives

• Revenue for the second quarter of 2025 significantly increased to $39.7 million from $6.4 million in Q2 2024, primarily due to government contracts.
• Net loss decreased to $15.0 million in Q2 2025 from $16.5 million in Q2 2024, and net loss per share improved to $0.07 from $0.09.
• Positive topline data from the Phase 1 norovirus vaccine trial showed statistically significant increases in antibody responses (141% for GI.1 and 94% for GII.4), supporting potential for improved protection.
• The norovirus program is on track for a potential Phase 2b study in the second half of 2025 and a Phase 3 trial as early as 2026, pending partnership or funding.
• The COVID-19 Phase 2b trial achieved rapid enrollment of approximately 5,000 participants before the stop work order, validating demand for an oral vaccine.
• An independent Data Safety Monitoring Board determined in July 2025 that the COVID-19 study could proceed without modification.
• The avian influenza vaccine demonstrated 100% protection against death in a robust ferret challenge model.
• Received $98.9 million in cash payments associated with the BARDA COVID-19 award as of June 30, 2025.

Negatives

• Received a stop work order on August 5, 2025, from the U.S. government, halting screening and enrollment for the COVID-19 Phase 2b trial.
• Cash, cash equivalents, and investments decreased to $26.3 million as of June 30, 2025, from $51.7 million as of December 31, 2024.
• Anticipated cash runway only extends into the first quarter of 2026, necessitating aggressive exploration of additional funding.
• Research and development expenses significantly increased to $49.7 million in Q2 2025 from $17.5 million in Q2 2024, primarily due to clinical trial costs.
• The company is seeking stockholder approval for a reverse stock split (1-for-5 to 1-for-20) to regain compliance with Nasdaq's minimum bid price requirement, indicating current stock price challenges.

Risks

• Uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates.
• The possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities.
• Regulatory authorities may not be satisfied with the design of and results from the clinical studies.
• The stop work order for the COVID-19 Phase 2b trial may result in further work on the trial being suspended or terminated.
• Decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate.
• Product candidates may not be approved by the FDA or non-U.S. regulatory authorities.
• Even if approved, product candidates may not achieve broad market acceptance.
• Collaborators may not attain development and commercial milestones.
• Manufacturing issues and delays due to events within, or outside of, control.
• Difficulties in production, particularly in scaling up initial production, including issues with production costs and yields, quality control, shortages of qualified personnel or key raw materials, and compliance with regulations.
• Inability to obtain, maintain, and enforce necessary patent and other intellectual property protection.
• Capital resources may be inadequate.
• Inability to obtain sufficient capital to fund operations on terms acceptable, if at all.
• Impact of government healthcare proposals and policies.
• Competitive factors.

Future Outlook

Vaxart intends to publish complete results of its norovirus Phase 1 study and expects to conduct a Phase 2b safety and immunogenicity study as early as the second half of 2025, pending partnership or funding, with a potential Phase 3 trial beginning as early as 2026. For the COVID-19 program, per protocol follow-up of all dosed participants will continue, with data from the 400-person sentinel cohort anticipated in Q1 2026 and topline data from the full trial in late 2026. The company also plans to publish preclinical results for its avian influenza program. Financially, Vaxart is aggressively exploring strategies to extend its cash runway beyond Q1 2026 through business development partnerships and non-dilutive funding options.

Management Comments

• "We continue to make significant progress in advancing our novel, oral vaccine platform."
• "The strong enrollment we achieved not only validates the demand for an alternative to current COVID-19 vaccines, but also enables us to generate meaningful data that will allow for us to assess the comparative efficacy and safety of our oral vaccine construct against an injectable mRNA comparator."
• "Our second-generation norovirus vaccine constructs demonstrated a statistically significant increase in antibody responses, which increases the probability of enhanced protection against this highly contagious virus."
• "We continue to hold productive conversations with potential partners that could support progression of our promising vaccine candidate to a Phase 2 trial later this year."
• "We remain committed to executing on our clinical trials with the goal of revolutionizing global public health with our oral vaccine platform."

Industry Context

The filing highlights the ongoing demand for alternative vaccine platforms, particularly oral vaccines, for widespread infectious diseases like COVID-19, norovirus, and influenza. This aligns with a broader industry trend towards diversifying vaccine delivery methods to improve accessibility, ease of administration (eliminating needle-stick injury risk), and storage/distribution (without refrigeration). The focus on highly contagious viruses like norovirus and influenza also reflects persistent public health needs for effective preventative measures. The stop work order for the COVID-19 trial, while a setback for Vaxart, also reflects the dynamic and evolving landscape of government funding and priorities in the post-pandemic vaccine development space.

Comparison to Industry Standards

• The oral vaccine platform offers a distinct advantage over traditional injectable vaccines by eliminating cold chain requirements and needle-stick injuries, positioning it uniquely in the vaccine delivery landscape.
• The 100% protection against death in a ferret model for the avian influenza vaccine represents a strong preclinical efficacy signal, comparable to promising early-stage data reported by other vaccine developers in animal challenge models.
• The statistically significant increases in antibody responses (141% for GI.1, 94% for GII.4) for the second-generation norovirus vaccine constructs demonstrate improved immunogenicity, a critical benchmark for advancing vaccine candidates.
• The rapid enrollment of approximately 5,000 participants in the COVID-19 trial, despite the subsequent stop work order, indicates a high level of public interest and demand for oral vaccine alternatives, potentially suggesting a more favorable public reception compared to some traditional vaccine trials.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution if a capital raise occurs; potential for increased share price and Nasdaq compliance if the reverse stock split is successful, but also risk of further price decline. Impact from clinical trial progress and setbacks.
• Employees: Continued employment and focus on clinical programs, but potential for uncertainty given the limited financial runway and the halt of a major trial.
• Customers (future vaccine recipients): Potential for novel oral vaccines for COVID-19, norovirus, and influenza, offering an alternative to injectables.
• Government (BARDA): Continued collaboration on COVID-19 vaccine follow-up, but the stop work order indicates a shift in government priorities or funding for the trial's enrollment phase.

Next Steps

• Publish the complete results of the norovirus Phase 1 study in a peer-reviewed journal.
• Conduct a Phase 2b safety and immunogenicity study for the norovirus vaccine, potentially starting in the second half of 2025, pending partnership or funding.
• Hold an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for the norovirus program.
• Potentially begin a Phase 3 trial for the norovirus vaccine as early as 2026.
• Continue per protocol follow-up for all dosed participants in the COVID-19 Phase 2b trial for up to 12 months post-vaccination.
• Anticipate data from the 400-person sentinel cohort of the COVID-19 trial in the first quarter of 2026.
• Anticipate topline data from the COVID-19 Phase 2b trial in late 2026.
• Publish results of the avian influenza preclinical studies in a peer-reviewed forum.
• Host a conference call on August 13, 2025, to discuss Q2 2025 results.
• Host a live stockholder fireside chat on August 20, 2025.
• Host a virtual special meeting of stockholders on September 5, 2025, to vote on a reverse stock split.
• Aggressively explore strategies to extend cash runway through business development partnerships and non-dilutive funding options.

Key Dates

Recommendation

Vaxart presents a mixed bag of developments. Positive early-stage clinical data for norovirus and influenza programs, coupled with significant revenue from government contracts, show promise for its oral vaccine platform. However, the unexpected stop work order for the large COVID-19 Phase 2b trial introduces significant uncertainty and delays a key program. The limited cash runway into Q1 2026 and the necessity of a reverse stock split to maintain Nasdaq listing highlight financial fragility and potential for further dilution. While the long-term potential of oral vaccines remains, the immediate operational and financial headwinds suggest a 'hold' position until there is more clarity on the COVID-19 trial's future, successful execution of funding strategies, and the outcome of the reverse stock split.

Keywords

Vaxart, VXRT, oral vaccine, norovirus, COVID-19, influenza, clinical trial, biotechnology, pharmaceutical, Q2 2025, financial results, reverse stock split, SEC filing